Sergey Orlov

Sergey Orlov

UNVERIFIED PROFILE

Are you Sergey Orlov?   Register this Author

Register author
Sergey Orlov

Sergey Orlov

Publications by authors named "Sergey Orlov"

Are you Sergey Orlov?   Register this Author

57Publications

2407Reads

11Profile Views

Encorafenib, Binimetinib, and Cetuximab in V600E-Mutated Colorectal Cancer.

N Engl J Med 2019 10 30;381(17):1632-1643. Epub 2019 Sep 30.

From the University of Texas M.D. Anderson Cancer Center, Houston (S.K., V.M.); West Cancer Center and Research Institute, OneOncology, Germantown, TN (A. Grothey); Memorial Sloan Kettering Cancer Center, New York (R.Y., A.K.); University Hospital Gasthuisberg and University of Leuven, Leuven, Belgium (E.V.C., J. Dekervel); the Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (J. Desai, C.G.); National Cancer Center Hospital East, Kashiwa, Japan (T.Y.); Hammersmith Hospital, Division of Cancer, Imperial College London (H.W.), and the Sarah Cannon Research Institute and University College London Cancer Institute (H.-T.A.), London, and the Christie NHS Foundation Trust/National Institute for Health Research Manchester Biomedical Research Centre, Manchester (M.B.) - all in the United Kingdom; the University of Campania Luigi Vanvitelli, Naples (F.C.), and Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padua (F.L., S.L.) - both in Italy; Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea (Y.S.H., T.-W.K.); the Netherlands Cancer Institute, Amsterdam (N.S., J.H.M.S.); Oslo University Hospital, Oslo (T.K.G.); Hospital Gregorio Marañón, Madrid (P.G.-A., A.C.F.), and Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, UVic, IOB-Quiron, Barcelona (E.E., J.T.) - both in Spain; Odense University Hospital, Odense, Denmark (P.P., L.S.T.); Pavlov First St. Petersburg State Medical University, St. Petersburg, Russia (S.O.); and Array BioPharma, Boulder, CO (A. Gollerkeri, C.K., K.M., M.P., J.C.-B., L.A., V.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1908075DOI Listing
October 2019

Variability in lung cancer response to ALK inhibitors cannot be explained by the diversity of ALK fusion variants.

Biochimie 2018 Nov 30;154:19-24. Epub 2018 Jul 30.

N.N. Petrov Institute of Oncology, St.-Petersburg, Pesochny, Leningradskaya 68, 197758, Russia; St.-Petersburg Pediatric Medical University, St.-Petersburg, Litovskaya 2, 194100, Russia; I.P. Pavlov St.-Petersburg State Medical University, St.-Petersburg, Lev Tolstoy Street 6-8, 197022, Russia; City Cancer Center, St.-Petersburg, Pesochny, Leningradskaya 68A, 197758, Russia; I.I. Mechnikov North-Western Medical University, St.-Petersburg, Kirochnaya Street 41, 191015, Russia; Institute of Medical Primatology, Sochi, Veseloye, Mira Street 177, 354376, Russia; St.-Petersburg State University, St.-Petersburg, Universitetskaya Naberezhnaya 7/9, 199034, Russia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biochi.2018.07.018DOI Listing
November 2018

Insulin downregulates C3 gene expression in human HepG2 cells through activation of PPARγ.

Eur J Cell Biol 2018 Apr 9;97(3):204-215. Epub 2018 Mar 9.

Department of Biochemistry, Institute of Experimental Medicine, St. Petersburg, Russia; Department of Embryology, St. Petersburg State University, St. Petersburg, Russia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejcb.2018.03.001DOI Listing
April 2018

Enzyme kinetics of cellulose hydrolysis of and oat hulls.

3 Biotech 2017 Oct 14;7(5):317. Epub 2017 Sep 14.

Laboratory of Bioconversion, Laboratory of Chemical Engineering Processes and Apparatuses, Institute for Problems of Chemical and Energetic Technologies, Siberian Branch of the Russian Academy of Sciences (IPCET SB RAS), Biysk, Altai Krai Russia 659322.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13205-017-0964-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5599380PMC
October 2017

Insulin-Mediated Downregulation of Apolipoprotein A-I Gene in Human Hepatoma Cell Line HepG2: The Role of Interaction Between FOXO1 and LXRβ Transcription Factors.

J Cell Biochem 2017 02 30;118(2):382-396. Epub 2016 Sep 30.

Department of Biochemistry, Institute of Experimental Medicine, Russian Academy of Medical Sciences, St. Petersburg, Russia.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/jcb.25651
Publisher Site
http://dx.doi.org/10.1002/jcb.25651DOI Listing
February 2017

FOXO1 and LXRα downregulate the apolipoprotein A-I gene expression during hydrogen peroxide-induced oxidative stress in HepG2 cells.

Cell Stress Chaperones 2017 01 28;22(1):123-134. Epub 2016 Nov 28.

Department of Biochemistry, Institute of Experimental Medicine, Russian Academy of Medical Sciences, Acad. Pavlov St., 12, St. Petersburg, 197376, Russia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12192-016-0749-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5225066PMC
January 2017

PPARγ Represses Apolipoprotein A-I Gene but Impedes TNFα-Mediated ApoA-I Downregulation in HepG2 Cells.

J Cell Biochem 2016 09 8;117(9):2010-22. Epub 2016 Feb 8.

Department of Biochemistry, Institute of Experimental Medicine, Russian Academy of Medical Sciences, St. Petersburg, Russia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcb.25498DOI Listing
September 2016

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.

J Clin Oncol 2015 Dec 31;33(34):4007-14. Epub 2015 Aug 31.

Karen Kelly, University of California, Davis, Comprehensive Cancer Center, Sacramento, CA; Nasser K. Altorki, New York Presbyterian Hospital-Weill Cornell Medical Center, New York, NY; Wilfried E.E. Eberhardt, University Hospital Essen, Essen, Germany; Mary E.R. O'Brien, Royal Marsden Hospital, London, United Kingdom; David R. Spigel, Sarah Cannon Research Institute, Nashville, TN; Lucio Crinò, Ospedale S. Maria della Misericordia, Perugia, Italy; Chun-Ming Tsai, Taipei General Hospital and National Yang-Ming University, Taipei, Taiwan; Joo-Hang Kim, Yonsei University Health System, Seoul; Eun Kyung Cho, Gachon University, Incheon, Korea; Philip C. Hoffman, The University of Chicago Medical Center, Chicago; Jiuzhou Wang and Margaret A. Foley, Astellas Pharma, Northbrook, IL; Sergey V. Orlov, I.P. Pavlov Medical University, St Petersburg, Russia; Piotr Serwatowski, Specjalistyczny Szpital, Sokolowskiego, Szczecin, Poland; Julie D. Horan, Novella Clinical, Boulder, CO; and Frances A. Shepherd, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2015/08/31/JCO.2015.61
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2015.61.8918
Publisher Site
http://dx.doi.org/10.1200/JCO.2015.61.8918DOI Listing
December 2015

Binding of ouabain and marinobufagenin leads to different structural changes in Na,K-ATPase and depends on the enzyme conformation.

FEBS Lett 2015 Sep 20;589(19 Pt B):2668-74. Epub 2015 Aug 20.

Faculty of Biology, M.V. Lomonosov Moscow State University, 119234 Moscow, Russia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.febslet.2015.08.011DOI Listing
September 2015

Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer.

J Clin Oncol 2015 Aug 13;33(24):2667-74. Epub 2015 Jul 13.

Giorgio Scagliotti and Silvia Novello, University of Turin, Orbassano, Torino; Adolfo Favaretto, Istituto Oncologico Veneto, Padova; Armando Santoro, Istituto Clinico Humanitas, Milan, Italy; Joachim von Pawel, Asklepios-Fachkliniken München-Gauting, Munich, Germany; Rodryg Ramlau, Poznań University of Medical Sciences, Poznań, Poland; Fabrice Barlesi, Aix Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille, France; Wallace Akerley, Huntsman Cancer Institute, Salt Lake City, UT; Sergey Orlov, St Petersburg State Medical University, St Petersburg, Russian Federation; David Spigel, Clinical Locations, Nashville, TN; Vera Hirsh, McGill University Health Centre, Montreal, Quebec; Frances A. Shepherd, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Lecia V. Sequist, Massachusetts General Hospital, Boston; Jeffrey S. Ross, Foundation Medicine, Cambridge; Brian Schwartz, ArQule, Woburn, MA; Alan Sandler, Genentech, San Francisco, CA; and Qiang Wang, Reinhard von Roemeling, and Dale Shuster, Daiichi Sankyo, Edison, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.60.7317DOI Listing
August 2015

Clinical genotyping and efficacy outcomes: exploratory biomarker data from the phase II ABIGAIL study of first-line bevacizumab plus chemotherapy in non-squamous non-small-cell lung cancer.

Lung Cancer 2014 Oct 2;86(1):67-72. Epub 2014 Aug 2.

Department of Clinical Oncology, State Key Laboratory of South China, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2014.07.019DOI Listing
October 2014

A correlative biomarker analysis of the combination of bevacizumab and carboplatin-based chemotherapy for advanced nonsquamous non-small-cell lung cancer: results of the phase II randomized ABIGAIL study (BO21015).

J Thorac Oncol 2014 Jun;9(6):848-55

*State Key Laboratory of Southern China, Hong Kong Cancer Institute, Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong, China; †Russian Research Oncology Center n.a. N.N. Blokhin of the Russian Academy of Medical Sciences, Moscow, Russia; ‡Országos Korányi TBC és Pulmonológiai Intézet, Budapest, Hungary; §Department of Pulmonology, Markusovszky University Hospital, Budapest, Hungary; ‖Arkhangelsk Regional Clinical Oncology Dispensary, Perm, Russia; ¶Department of Internal Medicine, National Taiwan University Hospital, Taipei City, Taiwan; #Roche Products Limited, Welwyn Garden City, Hertfordshire, United Kingdom; **F. Hoffmann-La Roche Ltd., Basel, Switzerland; and ††Department of Thoracic Oncology, Lung Clinic Grosshansdorf, Member of the German Center for Lung Research (DZL), Grosshansdorf, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000160DOI Listing
June 2014

Circular dichroism study of the interaction between mutagens and bilirubin bound to different binding sites of serum albumins.

Spectrochim Acta A Mol Biomol Spectrosc 2014 May 13;126:68-75. Epub 2014 Feb 13.

Department of Physics and Measurements, Institute of Chemical Technology, Prague, Technická 5, 166 28 Prague 6, Czech Republic. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.saa.2014.01.139DOI Listing
May 2014

Lung carcinomas with EGFR exon 19 insertions are sensitive to gefitinib treatment.

J Thorac Oncol 2014 Apr;9(4):e31-3

N.N. Petrov Institute of Oncology, St. Petersburg, Russia, St.Petersburg Pediatric Medical Academy, St.Petersburg, Russia N.N. Petrov Institute of Oncology, St. Petersburg, Russia City Oncological Hospital, St. Petersburg, Russia Institute of Pulmonology, St. Petersburg, Russia Regional Oncological Hospital, Ryazan, Russia Institute of Pulmonology, St. Petersburg, Russia N.N. Petrov Institute of Oncology, St. Petersburg, Russia St. Petersburg Pediatric Medical Academy, St.Petersburg, Russia N.N. Petrov Institute of Oncology, St. Petersburg, Russia N.N. Petrov Institute of Oncology, St. Petersburg, Russia, St.Petersburg Pediatric Medical Academy, St.Petersburg, Russia, I.I. Mechnikov North-Western Medical University, St. Petersburg, Russia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000106DOI Listing
April 2014

The location of the high- and low-affinity bilirubin-binding sites on serum albumin: ligand-competition analysis investigated by circular dichroism.

Biophys Chem 2013 Oct-Nov;180-181:55-65. Epub 2013 Jun 22.

Department of Analytical Chemistry, Institute of Chemical Technology, Prague, Technická 5, 166 28 Prague 6 Czech Republic. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03014622130009
Publisher Site
http://dx.doi.org/10.1016/j.bpc.2013.06.004DOI Listing
March 2014

Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.

J Clin Oncol 2013 Nov 7;31(32):4105-14. Epub 2013 Oct 7.

David R. Spigel, Thomas J. Ervin, and Davey B. Daniel, Sarah Cannon Research Institute; David R. Spigel, Tennessee Oncology, Nashville; Davey B. Daniel, Chattanooga Oncology Hematology Associates, Chattanooga, TN; Thomas J. Ervin, Florida Cancer Specialists, Fort Myers; Michael S. Wertheim, Hematology/Oncology Associates, Port St Lucie, FL; Rodryg A. Ramlau, Poznan University of Medical Sciences, Poznan; Maciej J. Krzakowski, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; Jerome H. Goldschmidt Jr, Blue Ridge Cancer Care, Christianburg, VA; George R. Blumenschein Jr, The University of Texas MD Anderson Cancer Center, Houston, TX; Gilles Robinet, University Hospital Morvan, Brest; Benoit Godbert, Centre Hospitalier Universitaire Nancy, Vandoeuvre-lès-Nancy; Fabrice Barlesi, Assistance Publique-Hôpitaux de Marseille, Aix Marseille University, Marseille, France; Ramaswamy Govindan, Washington University School of Medicine, St Louis, MO; Taral Patel, Mid Ohio Oncology/Hematology, Columbus, OH; Sergey V. Orlov, St Petersburg Pavlov State Medical University, St Petersburg, Russia; Wei Yu, Robert L. Yauch, Premal H. Patel, and See-Chun Phan, Genentech; Amy C. Peterson, Medivation, San Francisco, CA; and Jiping Zha, Crown Bioscience, Taicang City, China.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2013/10/07/JCO.2012.47
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2012.47.4189
Publisher Site
http://dx.doi.org/10.1200/JCO.2012.47.4189DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4878106PMC
November 2013

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

J Clin Oncol 2013 Sep 1;31(27):3327-34. Epub 2013 Jul 1.

Lecia V. Sequist, Massachusetts General Hospital and Harvard Medical School, Boston, MA; James Chih-Hsin Yang, National Taiwan University Hospital; Chun-Ming Tsai, Taipei Veterans General Hospital, Taipei; Wu-Chou Su, National Cheng Kung University Hospital, Tainan, Taiwan; Nobuyuki Yamamoto, Shizuoka Cancer Center, Shizuoka; Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, Yokohama, Japan; Kenneth O'Byrne, St James' Hospital, Dublin, Ireland; Vera Hirsh, McGill University, Montreal, Quebec, Canada; Tony Mok, Prince of Wales Hospital, Hong Kong, China; Sarayut Lucien Geater, Songklanagarind Hospital, Songkla, Thailand; Sergey Orlov, Pavlov State Medical University, St Petersburg; Vera Gorbunova, GU Russian Oncological Research Centre, Moscow, Russia; Michael Boyer, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia; Jaafar Bennouna, Institut de Cancérologie de l'Ouest-site René Gauducheau, Nantes, France; Ki Hyeong Lee, Chungbuk National University Hospital, Cheongju, South Korea; Riyaz Shah, Maidstone and Tunbridge Wells National Health Service Trust, Maidstone Hospital, Maidstone; Dan Massey, Victoria Zazulina, and Mehdi Shahidi, Boehringer Ingelheim, Bracknell, United Kingdom; and Martin Schuler, West German Cancer Center, University of Duisburg-Essen, Essen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.44.2806DOI Listing
September 2013

Detection of EGFR mutations and EML4-ALK rearrangements in lung adenocarcinomas using archived cytological slides.

Cancer Cytopathol 2013 Jul 13;121(7):370-6. Epub 2013 Feb 13.

Laboratory of Molecular Oncology, N.N. Petrov Institute of Oncology, St. Petersburg, Russia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncy.21281DOI Listing
July 2013

Hepatic nuclear factor 4α positively regulates complement C3 expression and does not interfere with TNFα-mediated stimulation of C3 expression in HepG2 cells.

Gene 2013 Jul 26;524(2):187-92. Epub 2013 Apr 26.

Department of Biochemistry, Institute of Experimental Medicine, Russian Academy of Medical Sciences, St. Petersburg 197376, Russia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.gene.2013.04.036DOI Listing
July 2013

Chiroptical properties of bilirubin-serum albumin binding sites.

Chirality 2013 Apr 5;25(4):257-63. Epub 2013 Mar 5.

Department of Analytical Chemistry, Institute of Chemical Technology, Prague, Technická 5, 166 28 Prague 6, Czech Republic.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/chir.22143DOI Listing
April 2013

Endogenous apolipoprotein A-I stabilizes ATP-binding cassette transporter A1 and modulates Toll-like receptor 4 signaling in human macrophages.

FASEB J 2012 May 23;26(5):2019-30. Epub 2012 Jan 23.

Institute of Experimental Medicine, Russian Academy of Medical Sciences, Department of Biochemistry, Acad. Pavlov St., 12, St. Petersburg, 197376, Russia.

View Article

Download full-text PDF

Source
http://www.fasebj.org/doi/10.1096/fj.11-193946
Publisher Site
http://dx.doi.org/10.1096/fj.11-193946DOI Listing
May 2012

PPARγ activates ABCA1 gene transcription but reduces the level of ABCA1 protein in HepG2 cells.

Biochem Biophys Res Commun 2010 Nov 15;402(3):477-82. Epub 2010 Oct 15.

Department of Biochemistry, Institute of Experimental Medicine, Russian Academy of Medical Sciences, 197376 St. Petersburg, Russia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbrc.2010.10.053DOI Listing
November 2010

Effect of TNFalpha on activities of different promoters of human apolipoprotein A-I gene.

Biochem Biophys Res Commun 2010 Jul 18;398(2):224-30. Epub 2010 Jun 18.

Department of Biochemistry, Institute of Experimental Medicine, Russian Academy of Medical Sciences, 197376 St. Petersburg, Russia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbrc.2010.06.064DOI Listing
July 2010

Role of the nuclear receptors HNF4 alpha, PPAR alpha, and LXRs in the TNF alpha-mediated inhibition of human apolipoprotein A-I gene expression in HepG2 cells.

Biochemistry 2009 Dec;48(50):11950-60

Department of Biochemistry, Institute of Experimental Medicine, Russian Academy of Medical Sciences, 197376 St. Petersburg, Russia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/bi9015742DOI Listing
December 2009

Complexes of plasmid DNA with basic domain 47-57 of the HIV-1 Tat protein are transferred to mammalian cells by endocytosis-mediated pathways.

J Biol Chem 2003 Oct 25;278(43):42625-36. Epub 2003 Jul 25.

Department of Cell Biology, St. Petersburg State University, 199034 St. Petersburg, Russia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M301431200DOI Listing
October 2003